← All Q32 Bio INC filings

Q32 Bio INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
QTTB
Q32 Bio INC
10-K: Q32 Bio Inc. Reports 2024 Financial Results and Provides Business Update
Q32 Bio Inc. announces its 2024 financial results, highlighting progress in clinical trials and a strategic refocus on bempikibart for alopecia areata.
NASDAQ
QTTB
Q32 Bio INC
10-K/A: Q32 Bio Inc. Completes Merger, Outlines Capital Structure and Governance
Q32 Bio Inc. finalizes its merger with Homology Medicines, Inc., detailing changes in capital stock, board composition, and executive compensation.
NASDAQ
QTTB
Q32 Bio INC
10-K: Homology Medicines Halts Development, Explores Strategic Options Amidst Merger with Q32 Bio
Homology Medicines has ceased development of its programs and reduced its workforce by 86% while pursuing strategic alternatives, including a merger with Q32 Bio.